Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Newron Pharmaceuticals SpA のCEOは誰ですか？
Prof. Stefan Weber は Newron Pharmaceuticals SpA の Chief Executive Officer で、2005 から在籍しています。
NWPHF の株価パフォーマンスは？
NWPHF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Newron Pharmaceuticals SpA の主な事業テーマや業界は？
Newron Pharmaceuticals SpA は Pharmaceuticals 業界、セクターは Health Care に属しています。
